Open Access

High frequency and prognostic value of MYD88 L265P mutation in diffuse large B‑cell lymphoma with R‑CHOP treatment

  • Authors:
    • Sisi Yu
    • Huaichao Luo
    • Meiling Pan
    • Luis Angel Palomino
    • Xiaoyu Song
    • Ping Wu
    • Jian‑Ming Huang
    • Zhihui Zhang
  • View Affiliations

  • Published online on: November 22, 2017     https://doi.org/10.3892/ol.2017.7472
  • Pages:1707-1715
  • Copyright: © Yu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

The aim of this study was to analyze the prevalence and prognostic value of myeloid differentiation factor 88 (MYD88) L265P in diffuse large B‑cell lymphoma (DLBCL) patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R‑CHOP). We assessed the MYD88 L265P mutation using an allele‑specific semi‑nested polymerase chain reaction method in 53 DLBCL patients treated with R‑CHOP. The MYD88 L265P mutation was detected in 16 of 53 DLBCL (30.19%) samples from patients treated with R‑CHOP. Age and location were statistically significantly associated with MYD88 L265P (P=0.025, 0.033, respectively), while treatment response and tumor recurrence were not. Univariate analysis showed that B symptoms (P=0.004) and Ki‑67 (P=0.03) were significantly associated with progression‑free survival (PFS), while MYD88 L265P showed no significant association with overall survival and PFS. Multivariate analysis showed that B symptoms were significantly associated with PFS. Our study suggests that the prognostic value of MYD88 L265P in DLBCL patients with R‑CHOP requires further research.

Related Articles

Journal Cover

February 2018
Volume 15 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Yu, S., Luo, H., Pan, M., Palomino, L.A., Song, X., Wu, P. ... Zhang, Z. (2018). High frequency and prognostic value of MYD88 L265P mutation in diffuse large B‑cell lymphoma with R‑CHOP treatment. Oncology Letters, 15, 1707-1715. https://doi.org/10.3892/ol.2017.7472
MLA
Yu, S., Luo, H., Pan, M., Palomino, L. A., Song, X., Wu, P., Huang, J., Zhang, Z."High frequency and prognostic value of MYD88 L265P mutation in diffuse large B‑cell lymphoma with R‑CHOP treatment". Oncology Letters 15.2 (2018): 1707-1715.
Chicago
Yu, S., Luo, H., Pan, M., Palomino, L. A., Song, X., Wu, P., Huang, J., Zhang, Z."High frequency and prognostic value of MYD88 L265P mutation in diffuse large B‑cell lymphoma with R‑CHOP treatment". Oncology Letters 15, no. 2 (2018): 1707-1715. https://doi.org/10.3892/ol.2017.7472